https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-862003-10-01 00:00:002019-02-15 08:50:28Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-302003-10-01 00:00:002019-02-15 08:49:36Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-09-01 / Int J Hyperthermia 2003 Sep-Oct;19(5):520-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-09-01 / Int J Hyperthermia 2003 Sep-Oct;19(5):520-332003-09-01 00:00:002019-02-15 08:48:25Thermal regulation of dendritic cell activation and migration from skin explants
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-09-01 / Anticancer Res. 2003 Sep-Oct;23(5b):4293-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-09-01 / Anticancer Res. 2003 Sep-Oct;23(5b):4293-3032003-09-01 00:00:002019-02-15 08:45:51Dendritic cell-based vaccines in breast and gynaecologic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-09-01 / J. Immunol. 2003 Sep;171(5):2366-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-09-01 / J. Immunol. 2003 Sep;171(5):2366-732003-09-01 00:00:002019-02-15 08:44:49Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-08-01 / J. Neurooncol. 2003 Aug-Sep;64(1-2):161-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-08-01 / J. Neurooncol. 2003 Aug-Sep;64(1-2):161-762003-08-01 00:00:002019-02-15 08:34:55The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-07-30 / J. Cancer Res. Clin. Oncol. 2003 Sep;129(9):521-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-07-30 / J. Cancer Res. Clin. Oncol. 2003 Sep;129(9):521-302003-07-30 00:00:002019-02-15 08:35:35Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-06-15 / J. Surg. Res. 2003 Jun;112(2):189-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-06-15 / J. Surg. Res. 2003 Jun;112(2):189-972003-06-15 00:00:002019-02-15 08:50:29In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-05-01 / Trends Endocrinol. Metab. 2003 May-Jun;14(4):156-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-05-01 / Trends Endocrinol. Metab. 2003 May-Jun;14(4):156-622003-05-01 00:00:002019-02-15 08:53:35Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-04-01 / Hematology 2003 Apr;8(2):97-104
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-04-01 / Hematology 2003 Apr;8(2):97-1042003-04-01 00:00:002019-02-15 08:32:45Dendritic cell-based immunotherapy for the treatment of hematological malignancies
